- Home
- KURA vs TBPH Comparison
KURA vs TBPH Comparison
Compare KURA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- TBPH
- Stock Information
- Founded
- KURA 2014
- TBPH 2013
- Country
- KURA United States
- TBPH United States
- Employees
- KURA N/A
- TBPH N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- TBPH Health Care
- Exchange
- KURA Nasdaq
- TBPH Nasdaq
- Market Cap
- KURA 561.9M
- TBPH 536.5M
- IPO Year
- KURA N/A
- TBPH N/A
- Fundamental
- Price
- KURA $6.47
- TBPH $11.13
- Analyst Decision
- KURA Strong Buy
- TBPH Strong Buy
- Analyst Count
- KURA 12
- TBPH 5
- Target Price
- KURA $24.50
- TBPH $16.60
- AVG Volume (30 Days)
- KURA 1.4M
- TBPH 217.2K
- Earning Date
- KURA 08-07-2025
- TBPH 08-04-2025
- Dividend Yield
- KURA N/A
- TBPH N/A
- EPS Growth
- KURA N/A
- TBPH N/A
- EPS
- KURA N/A
- TBPH N/A
- Revenue
- KURA $67,991,000.00
- TBPH $65,266,000.00
- Revenue This Year
- KURA $125.04
- TBPH $51.74
- Revenue Next Year
- KURA $83.75
- TBPH N/A
- P/E Ratio
- KURA N/A
- TBPH N/A
- Revenue Growth
- KURA N/A
- TBPH 6.11
- 52 Week Low
- KURA $5.41
- TBPH $7.44
- 52 Week High
- KURA $21.60
- TBPH $11.88
- Technical
- Relative Strength Index (RSI)
- KURA 55.28
- TBPH 51.03
- Support Level
- KURA $6.26
- TBPH $11.16
- Resistance Level
- KURA $6.74
- TBPH $11.44
- Average True Range (ATR)
- KURA 0.31
- TBPH 0.28
- MACD
- KURA 0.05
- TBPH -0.07
- Stochastic Oscillator
- KURA 75.25
- TBPH 19.35
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).